

## DAFTAR PUSTAKA

American College of Radiology. (2020). O-RADS MRI Risk Stratification System

Anton C, Carvalho FM, Oliveira EI, Maciel GA, Baracat EC, Carvalho JP. (2012). A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. *Clinics (Sao Paulo)*;67(5):437-41. doi: 10.6061/clinics/2012(05)06. PMID: 22666786; PMCID: PMC3351260.

Bast, R.C. (2010). Biomarkers for ovarian cancer: new technologies and targets to address persistently unmet needs. *Cancer biomarkers: section of a disease markers* 8(4-5): 161-6.

Bell DA. (2005) *Origins and molecular pathology of ovarian cancer. Modern Pathol.* ;18(S2):S19. doi: 10.1038/modpathol.3800306)

Brett M. R, Jennifer B. P, Thomas A. S, Brett M. R, Jennifer B. P, Thomas A. S. (2017). Epidemiology of ovarian cancer: a review. *Cancer Biol Med.*;14(1):9–32.

Cohen, J.G., White, M., Cruz, A., Farias-Eisner, R. (2014). Can we do better than CA125 in the early detection of ovarian cancer?. *World Journal of Biological Chemistry* 5(3): 286-300.

Dodge JE, Covens AL, Lacchetti C, Elit LM, Le T, Devries-Aboud M, Fung-Kee-Fung M. (2012). Gynecology Cancer Disease Site Group. Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. *Gynecol Oncol.* 2012 Jul;126(1):157-66.

Grabowska-Derlatka L, Derlatka P, Szeszkowski W, Cieszanowski A. (2016) Diffusion-Weighted Imaging of Small Peritoneal Implants in "Potentially" Early-Stage Ovarian Cancer. *Biomed Res Int.* 2016;2016:9254742. doi: 10.1155/2016/9254742. Epub 2016 Feb 28. PMID: 27022614; PMCID: PMC4789070.

Ekanayake CD, Munasinghe N, Kumarasinghe I, Rasnayake S.(2020) Elevated CA 125 level in a mucinous cystadenoma and a teratoma: a case report. *J Med Case Rep.* 2020 Sep 3;14(1):141. doi: 10.1186/s13256-020-02458-x. PMID: 32878645; PMCID: PMC7469355.

Felder, M., et al. (2014). Ovarian cancer diagnosis and beyond: The role of HE4 and mesothelin. *Expert Review of Obstetrics & Gynecology*, 9(7), 527-537.

Froyman W, Wynants L, Landolfo C, et al. (2017). Validation of the Performance of International Ovarian Tumor Analysis (IOTA) Methods in the Diagnosis of

Early Stage Ovarian Cancer in a Non-Screening Population. *Diagnostics* (Basel) ;7(2):E32.

Fujii, S., Kakite, S., Nishihara, K., Kanasaki, Y., Harada, T., Kigawa, J., et al. (2008) Diagnostic Accuracy of Diffusion-Weighted Imaging in Differentiating Benign from Malignant Ovarian Lesions. *Journal of Magnetic Resonance Imaging*, 28, 1149-1156. <https://doi.org/10.1002/jmri.21575>

Helga F. (2007). *Clinical Anatomy of Female Pelvis in : Hamm B, Forstner R, editor. MRI and CT of the Female Pelvis. Berlin: Springer, hal. 1-21.*

Lheureux S, Gourley C, Vergote I, Oza AM. (2019). Epithelial ovarian cancer. *Lancet*;393(10177):1240-1253.

Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. (2016). Ovarian cancer. *Nat Rev Dis Prim.*;2:1–22.

Meys EM, Kaijser J, Kruitwagen RF, Slangen BF, Van Calster B, Aertgeerts B, Verbakel JY, Timmerman D, Van Gorp T. Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. *Eur J Cancer*. 2016 May;58:17-29. doi: 10.1016/j.ejca.2016.01.007. Epub 2016 Feb 27. PMID: 26922169.

Nakae, M., Iwamoto, I., Fujino, T., Maehata, Y., Togami, S., Yoshinaga, M., et al. (2006). Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. *The journal of obstetrics and gynaecology research* 32(3): 309-14.

PDQ Adult Treatment Editorial Board. Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®): Health Professional Version. PDQ Cancer Information Summaries. (2021).

Scholler N, Urban N (2007). CA125 in ovarian cancer. *Biomark Med*. Dec;1(4):513-23.

Scholler, N., et al. (2007). CA-125: Current Use and Future Outlook. *Current Oncology*, 14(3), 238-250.

Smith CG. (2017). A Resident's Perspective of Ovarian Cancer. *Diagnostics* (Basel). Apr 27;7(2)

Sohaib SA, Sahdev A, Van Trappen P, Jacobs IJ, Reznick RH. (2003) *Characterization of adneksal mass lesions on MR imaging. AJR Am J Roentgenol* ;180(5):1297–1304)

Stewart C, Ralyea C, Lockwood S. (2019). Ovarian Cancer: An Integrated review. *Semin Oncol Nurs.*;35(2):151–6.

Thomassin-Naggara I, Dabi Y, Florin M, et al.(2023). O-RADS MRI SCORE: *An Essential First-Step Tool for the Characterization of Adnexal Masses*. *Journal of Magnetic Resonance Imaging : JMRI*. 2023 Aug. DOI: 10.1002/jmri.28947. PMID: 37550825.

Thomassin-Naggara I, Poncelet E, Jalaguier-Coudray A, et al.(2020). *Ovarianadnexal reporting data system magnetic resonance imaging (O-RADS MRI) score for risk stratification of Sonographically indeterminate adnexal masses*. *JAMA Netw Open* 2020;3:e1919896.

Thomassin-Naggara, I., Toussaint, I., Perrot, N., Rouzier, R., Cuenod, C.A., Bazot, M., et al. (2011) Characterization of Complex Adnexal Masses: Value of Adding Perfusion- and Diffusion-Weighted MR Imaging to Conventional MR Imaging. *Radiology*, 258, 793-803. <https://doi.org/10.1148/radiol.10100751>

van Nimwegen, L.W.E. and Mavinkurve-Groothuis, A.M.C. (2019) MR Imaging in Discriminating between Benign and Malignant Paediatric Ovarian Masses: A Systematic Review. *European Radiology*, 1-16. <https://doi.org/10.1007/s00330-019-06420-4>

Wang R, Li X, Li S, Fang S, Zhao C, Yang H, Yang Z. (2023). Clinical value of O-RADS combined with serum CA125 and HE4 for the diagnosis of ovarian tumours. *Acta Radiol*. Feb;64(2):821-828. doi: 10.1177/02841851221087376. Epub 2022 Mar 15. PMID: 35291856.

Woo YL, Kyrgiou M, Bryant A, Everett T, Dickinson HO. (2012). Centralisation of services for gynaecological cancers A Cochrane systematic review. *Gynecol Oncol*. Aug;126(2):286–90.

Xie WT, Wang YQ, Xiang ZS, Du ZS, Huang SX, Chen YJ, Tang LN. (2022). Efficacy of IOTA simple rules, O-RADS, and CA125 to distinguish benign and malignant adnexal masses. *J Ovarian Res*. 2022 Jan 23;15(1):15. doi: 10.1186/s13048-022-00947-9. PMID: 35067220; PMCID: PMC8785584.